Parallelism in the luteinizing hormone responses to opioid and dopamine antagonists in hyperprolactinemic women with pituitary microadenoma

J Clin Endocrinol Metab. 1986 Nov;63(5):1225-8. doi: 10.1210/jcem-63-5-1225.

Abstract

Endogenous opiate peptides are considered to inhibit LH secretion via a dopaminergic mechanism, and increased opioid inhibition of LH secretion has been found in some hyperprolactinemic women with a pituitary microadenoma. To assess the role of endogenous dopaminergic tone in the opioid regulation of LH secretion in such patients, LH responses to an opioid antagonist (naloxone) and a dopamine antagonist (metoclopramide) were determined in 11 women with a prolactinoma. Neither naloxone nor metoclopramide administration induced any change in serum LH levels in normal women during the early follicular phase. In contrast, 7 of the 11 hyperprolactinemic women responded to both antagonists with a significant increase in LH levels. The parallelism in the LH responses to both antagonists in these hyperprolactinemic patients lends further support to a functional link between opioid and dopamine regulation of LH secretion.

Publication types

  • Comparative Study

MeSH terms

  • Adenoma / blood
  • Adenoma / complications
  • Adult
  • Dopamine Antagonists*
  • Female
  • Humans
  • Hyperprolactinemia / blood*
  • Hyperprolactinemia / etiology
  • Luteinizing Hormone / metabolism*
  • Metoclopramide / pharmacology*
  • Naloxone / pharmacology*
  • Pituitary Neoplasms / blood
  • Pituitary Neoplasms / complications
  • Prolactin / blood

Substances

  • Dopamine Antagonists
  • Naloxone
  • Prolactin
  • Luteinizing Hormone
  • Metoclopramide